GLPwatch

Exenatide-loaded PLGA microspheres with improved glycemic control: in vitro bioactivity and in vivo pharmacokinetic profiles after subcutaneous administration to SD rats.

Peptides · 2013

Last updated 2026-05-28

Researchers developed a long-acting exenatide injection using microspheres designed to slowly release the drug over time. In tests on rats, a single dose reached its highest blood concentration of about 108 ng/ml within 1.3 hours and remained active for roughly 121 hours. The drug’s release pattern in the lab matched its behavior in the animals, with an 89% correlation between the two.

AI summary of the abstract below.

JournalPeptides, 2013
Citations25
Relative citation ratio1.19
NIH percentile56
Molecules exenatide
Conditions studied Type 2 Diabetes

Abstract

A subcutaneous exenatide delivery system was developed and characterized in vitro and in vivo. The results clearly showed that the exenatide loaded PLGA microspheres prepared by using a non-aqueous processing medium had low burst release and high drug encapsulation efficiency. Exenatide loaded in the microspheres preserved its bioactivity. The pharmacokinetics parameters were determined after subcutaneous administration of microspheres to SD rats. The plasma concentration of the single dose of the sustained-release microspheres attained C(max) of 108.19±14.92 ng/ml at t(max) of 1.33±0.58 h and the t(½) was 120.65±44.18 h. There was a linear correlation between the in vitro and in vivo release behavior (R²=0.888). Exenatide loaded microspheres may prove to have great potential for clinical use.

Verbatim abstract via PubMed 23770254 ↗

Related research